TDM shows where unnecessary use of IFX can be stopped in IBD patients

Infliximab therapeutic drug monitoring (TDM) in IBD can significantly reduce unnecessary use of the TNF inhibitor and has the potential to offer substantial cost savings, Austraian research shows. A study of all public TDM of infliximab for IBD across Australia between 1 July 2016 and 31 July 2017 has shown infliximab use could be reduced ...

Already a member?

Login to keep reading.

© 2021 the limbic